Clinical Trial Update: Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating the EGFR inhibitors osimertinib and gefitinib in EGFR-inhibitor naïve patients with advanced EGFR-mutant non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING